BiomX (PHGE) Cash from Operations (2018 - 2026)
BiomX (PHGE) posted Cash from Operations of 5414000.0 for Q1 2026, down 23.44% sequentially from 4386000.0 in Q4 2025, and up 37.86% YoY from 3927291.26 in Q1 2025.
BiomX (PHGE) Cash from Operations (2018 - 2026) Analysis & Trends
BiomX has reported Cash from Operations for 9 years, with the latest figure at 5414000.0 in Q1 2026.
- Quarterly Cash from Operations rose 37.86% year-over-year to 5414000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 23092000.0 (up 32.75% YoY) and the FY2025 annual result came in at 26390000.0, up 28.64% from the prior year.
- Cash from Operations eased to 5414000.0 in Q1 2026 per PHGE's latest filing, from 4386000.0 in the prior quarter.
- Over five years, Cash from Operations peaked at 4077000.0 in Q2 2023 and troughed at 11237000.0 in Q2 2024.
- A 5-year average of 6737812.5 and a median of 6265500.0 in 2023 frame the typical range for Cash from Operations.
- The sharpest annual moves came in 2023 and 2024: Cash from Operations jumped 55.12% in 2023, then sank 175.62% in 2024.
- Over 5 years, Cash from Operations stood at 7168000.0 in 2022, then rose by 12.92% to 6242000.0 in 2023, then decreased by 0.75% to 6289000.0 in 2024, then surged by 30.26% to 4386000.0 in 2025, then retreated by 23.44% to 5414000.0 in 2026.
- According to Business Quant data, Cash from Operations over the past three periods registered 5414000.0, 4386000.0, and 7183000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Ops. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 1.13 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 813.00 Mn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | - |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | -526.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 462.82 Mn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 326.72 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | -88.83 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 728.46 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 360.27 Mn |
| 10 | BiomX | 361,408.40 | -806,591.60 | - | -5.41 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -5.41 Mn |
| Mar 31, 2026 | -5.41 Mn |
| Dec 31, 2025 | -4.39 Mn |
| Dec 31, 2025 | -4.39 Mn |
| Sep 30, 2025 | -7.18 Mn |
| Sep 30, 2025 | -7.18 Mn |
| Jun 30, 2025 | -6.11 Mn |
| Jun 30, 2025 | -6.11 Mn |
| Mar 31, 2025 | -8.71 Mn |
| Mar 31, 2025 | -8.71 Mn |
| Dec 31, 2024 | -6.29 Mn |
| Dec 31, 2024 | -6.29 Mn |
| Sep 30, 2024 | -8.10 Mn |
| Sep 30, 2024 | -8.10 Mn |
| Jun 30, 2024 | -11.24 Mn |
| Jun 30, 2024 | -11.24 Mn |
| Dec 31, 2023 | -6.24 Mn |
| Dec 31, 2023 | -6.24 Mn |
| Sep 30, 2023 | -5.92 Mn |
| Sep 30, 2023 | -5.92 Mn |